Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The p53-MDM2 axis is a critical regulatory pathway in cell biology, particularly in the context of tumor suppression and cancer development. It centers on the interaction between the tumor suppressor protein p53 and its primary negative regulator, MDM2. p53 is a transcription factor that responds to cellular stress by inducing cell cycle arrest, apoptosis, and DNA repair. MDM2 is an E3 ubiquitin ligase that binds to p53, inhibiting its transcriptional activity and promoting its degradation. The MDM2 gene is a direct transcriptional target of p53, forming an autoregulatory feedback loop. Dysregulation of this axis is a common event in cancer.
Inhibition of MDM2-p53 interaction, leading to p53 stabilization and activation of its downstream targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on p53-MDM2 Axis.